Compare SRI & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SRI | PLRX |
|---|---|---|
| Founded | 1965 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 172.9M | 93.3M |
| IPO Year | 1997 | 2020 |
| Metric | SRI | PLRX |
|---|---|---|
| Price | $5.94 | $1.24 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 1 | 11 |
| Target Price | ★ $16.00 | $3.79 |
| AVG Volume (30 Days) | 140.2K | ★ 1.8M |
| Earning Date | 11-05-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $874,357,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $7.68 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.54 | $1.10 |
| 52 Week High | $9.10 | $15.00 |
| Indicator | SRI | PLRX |
|---|---|---|
| Relative Strength Index (RSI) | 48.26 | 34.01 |
| Support Level | $5.54 | $1.17 |
| Resistance Level | $6.35 | $1.35 |
| Average True Range (ATR) | 0.22 | 0.12 |
| MACD | 0.10 | -0.03 |
| Stochastic Oscillator | 55.17 | 15.38 |
Stoneridge Inc is a manufacturer of electrical and electronic components used in automotive vehicles. The company produces instrumentation systems, vehicle management electronics, application-specific switches and actuators, sensors, security alarms, and vehicle tracking devices and monitoring services for commercial, automotive, off-highway, and agricultural vehicle markets. The company has three reportable segments: Control Devices, Electronics, and Stoneridge Brazil. It generates the majority of its revenue from the Electronics segment that produces driver information systems, camera-based vision systems, connectivity, and compliance products, and electronic control units. Its geographic segments include America, South America, Europe and Other.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.